Clinical Trial Update: Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating KI1106 for dyslipidemias in patients not adequately controlled on atorvastatin, with LDL-C properly controlled.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• KI1106 (KI1106)

Snippet

Sponsor: Kuhnil Pharmaceutical Co., Ltd. | Conditions: Dyslipidemias | Phase 3 | Status: COMPLETED